Berger Montague Announces Class Action Lawsuit Against Tenax Therapeutics Following Phase 3 Trial Failure
Law firm Berger Montague has announced a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) on behalf of investors who acquired securities between November 13, 2023, and August 7, 2026. The lawsuit alleges that the company and its officers misrepresented the development prospects of TNX-103, an oral levosimendan candidate for pulmonary hypertension. The legal action follows a significant stock price collapse on August 10, 2026, after Tenax reported that its Phase 3 LEVEL trial failed to meet both its primary endpoint and key secondary endpoints. This clinical failure resulted in the company's share price dropping approximately 89.77%, falling from its previous levels to close at $1.38 per share. Investors seeking to be appointed as lead plaintiffs have until December 28, 2026, to submit their applications. The complaint is filed in the United States District Court for the Middle District of North Carolina.